Sanofi replaces its CEO, profits fall in 2023

French pharmaceutical giant SanofiHis profitability slowed in 2023, an appointment he announced on Thursday, February 1. François-Xavier Rogeras of April 1 as the new financial director replacing Jean-Baptiste Chasseloup de Chatillon. “François-Xavier Roger will be appointed Chief Financial Officer and member of Sanofi’s Executive Committee from April 1, 2024” And “He will succeed Jean-Baptiste Chasseloup de Chatillon, who chose to leave Sanofi to take over the direction of the Apprentis d’Auteuil foundation”which helps young people with difficulties, according to a press release from the group.

Mr. Roger, who spent the first 14 years of his career in the pharmaceutical industry in different countries, was a financial director. Nestlé after holding the same position in the Japanese laboratory for more than eight years Takeda Pharmacy from 2013 to 2015. From 2000 to 2008, he was the financial director. Everyone Asia then finance, treasury and tax director of the Danone group. Between 2008 and 2013, he was the CFO of Millicom, a global telephone operator.


Sanofi joins startup Aqemia in artificial intelligence

The activity of the drug Dupixent

Sanofi also posted a net profit 5,436 billion euros For the 2023 financial year, more than a third less than in 2022. The net profit from the activity, an indicator in favor of the group, which excludes exceptional effects, decreased by 1.8%, 10.15 billion dinars. Net operating profit per share (EPS), another important indicator for Sanofi, is 8.11 euros compared to 8.26 in 2022. However, at a constant exchange rate, it grows by 5.4%. Its turnover stood at 43.07 billion euros (+0.2% in published data), below the consensus of Bloomberg and Factset analysts, but at constant exchange rates, sales increased by 5.3%.

He was driven by activity once again successful drug Dupixent sales increased by 34%, to 10,715 million euros, but also the evolution of vaccines (+8.3%), driven by marketing. Beyfortus (547 million euros) to protect babies against respiratory syncytial virus (RSV), which causes bronchiolitis. By 2024, Sanofi expects to make business EPS “suffering from low numbers” because of “expected tax rate increase” It predicts that EPS will be 21%, excluding this effect “Approximately stable”.

Leave a comment